SCHEMBL30120906

SCHEMBL30120906

CC(C)(C)c1ccccc1Oc1ccncc1N

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P2RY1 P47900 11/20 0.40
CA12 O43570 3/20 0.39
CA2 P00918 3/20 0.39
CA9 Q16790 3/20 0.39
CA14 Q9ULX7 3/20 0.39
NISCH Q9Y2I1 1/20 0.37
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
LMNA P02545 1/20 0.35
CA1 P00915 2/20 0.35
P2RY14 Q15391 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306805 1.00 P2RY1 (0.40) P2RY1CA12CA2CA9CA14
SCHEMBL397028 0.81 ALDH1A1 (0.48) P2RY1TDP1ALDH1A1GAACYP1A2
SCHEMBL30500977 0.77 ALDH1A1 (0.48) P2RY1CA2NISCHHTTNPSR1
SCHEMBL127278 0.77 ALDH1A1 (0.48) P2RY1CA2NISCHHTTNPSR1
SCHEMBL1306618 0.76 ALDH1A1 (0.46) HTTNPSR1TDP1ALDH1A1GAA
SCHEMBL11275925 0.76 PTGS1 (0.50) CA12CA2CA9CA14HTT
SCHEMBL17678671 0.76 CA12 (0.39) CA12CA2CA9CA14HTT
SCHEMBL1307934 0.75 P2RY1 (0.36) P2RY1CA12CA2CA9CA14
SCHEMBL14008970 0.74 LMNA (0.49) P2RY1TDP1ALDH1A1LMNA
SCHEMBL9853590 0.73 CYP3A4 (0.46) CA12CA2CA9CA14HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240269120-A1 Method for Treating an Autoimmune and Inflammatory Disease CELLESTIA BIOTECH AG (CH) 2024-08-15 US claimed
EP-4346816-A2 COMPOUNDS FOR USE IN A METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE Cellestia Biotech AG (CH) 2024-04-10 EP claimed
CN-117794536-A Compounds for use in methods of treating autoimmune and inflammatory diseases 塞莱斯蒂亚生物技术股份公司 2024-03-29 CN claimed
WO-2022253794-A2 METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE CELLESTIA BIOTECH AG (CH) 2022-12-08 WO claimed
US-20240269120-A1 Method for Treating an Autoimmune and Inflammatory Disease CELLESTIA BIOTECH AG (CH) 2024-08-15 US disclosed
EP-4346816-A2 COMPOUNDS FOR USE IN A METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE Cellestia Biotech AG (CH) 2024-04-10 EP disclosed
CN-117794536-A Compounds for use in methods of treating autoimmune and inflammatory diseases 塞莱斯蒂亚生物技术股份公司 2024-03-29 CN disclosed
WO-2022253794-A2 METHOD FOR TREATING AN AUTOIMMUNE AND INFLAMMATORY DISEASE CELLESTIA BIOTECH AG (CH) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269120-A1 Method for Treating an Autoimmune and Inflammatory Disease SERPINB1, TNF, MPO P2RY1 878/4885CA12 294/4885CA2 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.